Travere Therapeutic TVTX
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 15th percentile, 5-year average -29.7x
Near the top of its 5-year range · 96th percentile, 5-year average 30.6x
#5315 of 5331 stocks by PB (1 = cheapest)
Above its usual level · 71st percentile, 5-year average 6.3x
#4308 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 215.53 | – | 30.56 | 96% (pricier than usual) | #5315 of 5331 (1 = cheapest) |
| PE | -38.96 | 17.21 | -29.66 | 15% (cheaper than usual) | – |
| PS | 7.47 | 4.45 | 6.28 | 71% (pricier than usual) | #4308 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on TVTX.
Sign in to join the discussion.